DS
ASTX

David Shaw’s ASTEX PHARMACEUTICALS, INC COM ASTX Stock Holding History

David Shaw’s Portfolio ASTX Stock Details ASTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,054
Closed -$124K – 4619
2013
Q2 		$124K Buy
+30,054
New +$162K ﹤0.01% 3850

Other funds holding ASTX

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

David Shaw's ASTX Position: Q3 2013 in Review

David Shaw sold out of ASTEX PHARMACEUTICALS, INC COM (ASTX) in Q3 2013, closing a stake of 30,054 shares — an estimated $124K sold.

David Shaw first reported a position in ASTX in Q2 2013 and held it in 1 quarter. The position peaked at $124K in Q2 2013. 123 funds tracked by Wall St. Rank hold ASTX as of Q3 2013.

  • David Shaw reported no remaining ASTEX PHARMACEUTICALS, INC COM position as of Q3 2013 after selling out during the quarter.
  • David Shaw sold 30,054 ASTEX PHARMACEUTICALS, INC COM shares in Q3 2013, an estimated $124K.
  • David Shaw first reported a position in ASTEX PHARMACEUTICALS, INC COM in Q2 2013 and held it in 1 quarter.
  • David Shaw's ASTEX PHARMACEUTICALS, INC COM position peaked at $124K in Q2 2013.
  • 123 funds tracked by Wall St. Rank held ASTEX PHARMACEUTICALS, INC COM as of Q3 2013.

Based on D.E. Shaw & Co's 13F filing for Q3 2013, filed 14 Nov 2013.